References
1. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med 2020 ; 383(23): 2255-73.
2. Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 2021 ; 11(1): 316-29.
3. Cavalli G, Farina N, Campochiaro C, De Luca G, Della-Torre E, Tomelleri A, Dagna L. Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-Inflammation: A comprehensive review of available and emerging evidence at the peak of the pandemic. Front Pharmacol 2020 ; 11: 598308.
4. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med2021 ; 384(8): 693-704.
5. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Intern Med 2021 ; 181(1): 32-40.
6. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med 2020 ; 383(24): 2333-44.
7. Horby PW, Campbell M, Staplin N, Brightling CE, Sarkar R, Thomas K, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv preprint doi: https://doi.org/10.1101/2021.02.11.21249258.
8. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-immunomodulatory therapy in COVID-19. Drugs 2020 ; 80(13): 1267-92.
9. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020 ; 395(10223): e30-e1.
10. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021 ; 384(9): 795-807.
11. Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al; STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021 Jun 16. doi: 10.1056/NEJMoa2101643. Epub ahead of print.
12. Prokop M, van Everdingen W, van Rees Vellinga T, Quarles van Ufford H, Stöger L, Beenen L, et al. CO-RADS: A categorical CT assessment scheme for patients suspected of having COVID-19 definition and evaluation. Radiology 2020 ; 296(2): E97-E104.
13. Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs2017 ; 77(18): 1987-2001.
14. Moiseev S, Avdeev S, Brovko M, Bulanov N, Tao E, Fomin V. Outcomes of intensive care unit patients with COVID-19: a nationwide analysis in Russia. Anaesthesia 2021 ; 76 Suppl 3: 11-2.